Alembic Limited has informed the Exchange regarding Resignation of Mrs. Malika Amin from the position of Managing Director & CEO w.e.f. January 01, 2026. She will continue as Non-Executive Director of the Company liable to retire by rotation.
ALEMBICLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Limited reported its Q1 FY26 (ended June 30, 2025) results alongside a leadership change. Consolidated revenue from operations stood at Rs. 4,975 lakhs, marginally down from Rs. 5,078 lakhs in the same quarter last year. Net profit after tax (including share of associate Alembic Pharmaceuticals) rose to Rs. 6,164 lakhs from Rs. 5,582 lakhs, with EPS at Rs. 2.40 versus Rs. 2.17. The API business grew about 21% year-on-year to Rs. 1,295 lakhs, while real estate revenue declined to Rs. 3,680 lakhs. Mrs. Malika Amin will resign as Managing Director & CEO effective January 1, 2026, and will continue on the board as a Non-Executive Director. Her son, Mr. Udit Amin (currently a Non-Executive Non-Independent Director), will be appointed as Managing Director for 5 years effective October 1, 2025, subject to shareholder and other approvals.
This is an orderly, pre-announced family succession with the outgoing MD & CEO staying on the board, likely to be viewed positively by investors for continuity. Q1 results are broadly stable, with the API segment driving growth and the real estate business showing some softness.